MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2020.08.046

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2020

Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease.

Jackson William C, Tang Ming, Maurino Christopher, Mendiratta-Lala Mishal, Parikh Neehar D, Matuszak Martha M, Dow Janell S, Cao Yue, Mayo Charles S, Ten Haken Randall K, Schipper Matthew J, Cuneo Kyle C, Owen Dawn, Lawrence Theodore S

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

PURPOSE: Previous reports of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) suggest unacceptably high rates of toxicity in patients with Child-Turcotte-Pugh (CTP) B liver disease. We hypothesized that an individualized adaptive treatment approach based on midtreatment liver function would maintain good local control while limiting toxicity in this population.

METHODS AND MATERIALS: Patients with CTP-B liver disease and HCC were treated on prospective trials of individualized adaptive SBRT between 2006 and 2018. Patients underwent pre- and midtreatment liver function assessments using indocyanine green. Treatment-related toxicity was defined as a ≥2-point increase in CTP score from pretreatment within 6 months of treatment. In addition, we performed analyses with a longitudinal model to assess changes in CTP score over 12 months after SBRT.

RESULTS

Eighty patients with CTP-B (median tumor size, 2.5 cm) were treated: 37 patients were CTP-B-7, 28 were CTP-B-8, and 15 were CTP-B-9. The median treatment dose was 36 Gy in 3 fractions. One-year local control was 92%. In a multivariate model controlling for tumor size, treatment dose, and baseline CTP score, higher treatment dose was associated with improved freedom from local progression (hazard ratio: 0.97; 95% confidence interval, 0.94-1.00; P = .04). Eighteen patients (24%) had a ≥2-point increase in CTP score within 6 months of SBRT. In a longitudinal model assessing changes in CTP score over 12 months after SBRT, controlling for baseline CTP and tumor size, increasing mean liver dose was associated with larger increases in CTP score (P = .04).

CONCLUSIONS

An individualized adaptive treatment approach allows for acceptable toxicity and effective local control in patients with HCC and CTP-B liver disease. Because increasing dose may increase both local control and toxicity, further work is needed to optimize treatment in patients with compromised liver function.

Для цитирования: Jackson William C, Tang Ming, Maurino Christopher, Mendiratta-Lala Mishal, Parikh Neehar D, Matuszak Martha M, Dow Janell S, Cao Yue, Mayo Charles S, Ten Haken Randall K, Schipper Matthew J, Cuneo Kyle C, Owen Dawn, Lawrence Theodore S. Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease.. International journal of radiation oncology, biology, physics. 2020. DOI: 10.1016/j.ijrobp.2020.08.046.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.